|
BE794333A
(fr)
|
1972-01-20 |
1973-07-19 |
Wyeth John & Brother Ltd |
Composes heterocycliques azotes therapeutiques
|
|
GB1507462A
(en)
|
1974-03-21 |
1978-04-12 |
Gallardo Antonio Sa |
N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
|
|
US3983234A
(en)
|
1974-07-04 |
1976-09-28 |
Sandoz Ltd. |
Treatment of dyskinesias
|
|
JPS5152176A
(https=)
|
1974-10-12 |
1976-05-08 |
Yoshitomi Pharmaceutical |
|
|
JPS5285174A
(en)
|
1976-01-05 |
1977-07-15 |
Yoshitomi Pharmaceut Ind Ltd |
Novel urea or thiourea derivatives
|
|
GB1586468A
(en)
|
1976-10-29 |
1981-03-18 |
Anphar Sa |
Piperidine derivatives
|
|
CA1140119A
(en)
|
1978-04-03 |
1983-01-25 |
Joseph Torremans |
N-heterocyclyl-4-piperidinamines
|
|
US4255432A
(en)
|
1979-09-06 |
1981-03-10 |
Syntex (U.S.A.) Inc. |
8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
|
|
US4332804A
(en)
|
1981-03-23 |
1982-06-01 |
Syntex (U.S.A.) Inc. |
9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
|
|
US4353901A
(en)
|
1981-10-19 |
1982-10-12 |
Syntex (U.S.A.) Inc. |
9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
|
|
US4353900A
(en)
|
1981-10-19 |
1982-10-12 |
Syntex (U.S.A.) Inc. |
9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
|
|
GB8527052D0
(en)
|
1985-11-02 |
1985-12-04 |
Beecham Group Plc |
Compounds
|
|
GB8621892D0
(en)
|
1986-09-11 |
1986-10-15 |
Lundbeck & Co As H |
Organic compound
|
|
FR2642069B1
(fr)
|
1989-01-20 |
1991-04-12 |
Rhone Poulenc Sante |
Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
|
|
US5214055A
(en)
|
1990-05-18 |
1993-05-25 |
Adir Et Compagnie |
Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
|
|
US5216165A
(en)
|
1990-10-03 |
1993-06-01 |
American Home Products Corporation |
N-substituted aminoquinolines as analgesic agents
|
|
IT1252227B
(it)
|
1991-12-17 |
1995-06-05 |
Ciba Geigy Spa |
Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
|
|
US5595872A
(en)
|
1992-03-06 |
1997-01-21 |
Bristol-Myers Squibb Company |
Nucleic acids encoding microsomal trigyceride transfer protein
|
|
CA2123728A1
(en)
|
1993-05-21 |
1994-11-22 |
Noriyoshi Sueda |
Urea derivatives and their use as acat inhibitors
|
|
EP0700385A1
(en)
|
1993-05-26 |
1996-03-13 |
Smithkline Beecham Laboratoires Pharmaceutiques |
Novel compounds
|
|
IL110298A
(en)
|
1993-07-13 |
1999-04-11 |
Brann Mark Robert |
Identification of ligands by selective amplification of cells transfected with receptors
|
|
DE4404183A1
(de)
|
1994-02-10 |
1995-08-17 |
Merck Patent Gmbh |
4-Amino-1-piperidylbenzoylguanidine
|
|
US5795894A
(en)
|
1995-05-02 |
1998-08-18 |
Schering Corporation |
Piperazino derivatives as neurokinn antagonists
|
|
BR9610277A
(pt)
|
1995-08-31 |
1999-07-06 |
Schering Corp |
Derivados de piperazino como antagonistas de neurowuinina
|
|
DE69633245T2
(de)
|
1995-09-29 |
2005-09-08 |
Eli Lilly And Co., Indianapolis |
Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
|
|
PT871440E
(pt)
|
1995-12-07 |
2006-07-31 |
Daniel C Javitt |
Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
|
|
JP2001519766A
(ja)
|
1996-04-03 |
2001-10-23 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシルタンパク質トランスフェラーゼの阻害剤
|
|
DE69729583T2
(de)
|
1996-04-17 |
2005-06-09 |
Bristol-Myers Squibb Pharma Co. |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
|
|
US5869488A
(en)
|
1996-05-01 |
1999-02-09 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
|
US5877173A
(en)
|
1996-08-28 |
1999-03-02 |
Washington University |
Preventing neuronal degeneration in Alzheimer's disease
|
|
DE59711622D1
(de)
|
1996-09-10 |
2004-06-17 |
Boehringer Ingelheim Pharma |
Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
|
DE19643331A1
(de)
|
1996-10-21 |
1998-04-23 |
Thomae Gmbh Dr K |
1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6057338A
(en)
|
1997-04-04 |
2000-05-02 |
Merck & Co., Inc. |
Somatostatin agonists
|
|
WO1998050534A1
(en)
|
1997-05-08 |
1998-11-12 |
Smithkline Beecham Corporation |
Protease inhibitors
|
|
GB9718833D0
(en)
|
1997-09-04 |
1997-11-12 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
IL138192A0
(en)
|
1998-03-11 |
2001-11-25 |
Smithkline Beecham Plc |
Controlled release oral dosage forms
|
|
MXPA00010060A
(es)
|
1998-04-14 |
2004-04-23 |
Arena Pharm Inc |
Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
|
|
US6140509A
(en)
|
1998-06-26 |
2000-10-31 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
|
|
GB9816263D0
(en)
|
1998-07-24 |
1998-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US6358698B1
(en)
|
1998-10-07 |
2002-03-19 |
Acadia Pharmacueticals Inc. |
Methods of identifying inverse agonists of the serotonin 2A receptor
|
|
AU762345B2
(en)
|
1998-10-16 |
2003-06-26 |
Asubio Pharma Co., Ltd. |
Aminophenoxyacetic acid derivatives as neuroprotectants
|
|
US6150393A
(en)
|
1998-12-18 |
2000-11-21 |
Arena Pharmaceuticals, Inc. |
Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
|
|
EP1013276A1
(en)
|
1998-12-23 |
2000-06-28 |
Pfizer Inc. |
Aminoazacycloalkanes as CCR5 modulators
|
|
WO2000056335A1
(en)
|
1999-03-24 |
2000-09-28 |
The Regents Of The University Of California |
Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
|
|
US6399619B1
(en)
|
1999-04-06 |
2002-06-04 |
Merck & Co., Inc. |
Pyrrolidine modulators of chemokine receptor activity
|
|
WO2000069810A1
(en)
|
1999-05-17 |
2000-11-23 |
Novo Nordisk A/S |
Glucagon antagonists/inverse agonists
|
|
US20040229908A1
(en)
|
1999-07-13 |
2004-11-18 |
Jodi Nelson |
Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
|
|
US20050148018A1
(en)
|
1999-10-07 |
2005-07-07 |
David Weiner |
Methods of identifying inverse agonists of the serotonin 2A receptor
|
|
FR2802206B1
(fr)
|
1999-12-14 |
2005-04-22 |
Sod Conseils Rech Applic |
Derives de 4-aminopiperidine et leur utilisation en tant que medicament
|
|
US7022698B2
(en)
|
1999-12-28 |
2006-04-04 |
U & I Pharmaceuticals, Ltd. |
Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
|
|
ES2278729T3
(es)
|
2000-03-06 |
2007-08-16 |
Acadia Pharmaceuticals Inc. |
Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina.
|
|
GB0011838D0
(en)
|
2000-05-17 |
2000-07-05 |
Astrazeneca Ab |
Chemical compounds
|
|
US20020099076A1
(en)
|
2000-05-25 |
2002-07-25 |
Richard Scheyer D. |
Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
|
|
DE60141752D1
(de)
|
2000-06-30 |
2010-05-20 |
Innogenetics Nv |
Differentielle diagnose von neurologischen krankheiten
|
|
HUP0300810A2
(hu)
|
2000-07-20 |
2003-08-28 |
M.G.V.S. Ltd. |
Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
|
|
IL154363A0
(en)
|
2000-09-25 |
2003-09-17 |
Actelion Pharmaceuticals Ltd |
Substituted amino-aza-cycloalkanes useful against malaria
|
|
US20020173549A1
(en)
|
2000-11-08 |
2002-11-21 |
Wurtman Richard J. |
Compositions and methods for treatment of mild cognitive impairment
|
|
WO2002076464A1
(en)
|
2001-03-22 |
2002-10-03 |
Arena Pharmaceuticals, Inc. |
Anti-psychosis combination
|
|
GB0108099D0
(en)
|
2001-03-30 |
2001-05-23 |
Hoffmann La Roche |
Aminopiperidine derivatives
|
|
ATE516030T1
(de)
|
2001-10-02 |
2011-07-15 |
Acadia Pharm Inc |
Benzimidazolidinon-derivate als muscarinische mittel
|
|
MXPA04006280A
(es)
|
2001-12-28 |
2004-09-27 |
Acadia Pharm Inc |
Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
|
|
WO2003062206A2
(en)
|
2002-01-23 |
2003-07-31 |
Arena Pharmaceuticals, Inc. |
Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
UY27668A1
(es)
|
2002-02-20 |
2003-10-31 |
Pfizer Prod Inc |
Composición de ziprasidona y controles sintéticos
|
|
GB0208279D0
(en)
|
2002-04-10 |
2002-05-22 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1562937A2
(en)
|
2002-06-24 |
2005-08-17 |
Acadia Pharmaceuticals Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
US7538222B2
(en)
|
2002-06-24 |
2009-05-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
US7253186B2
(en)
|
2002-06-24 |
2007-08-07 |
Carl-Magnus Andersson |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
WO2004039322A2
(en)
|
2002-10-29 |
2004-05-13 |
Miicro, Inc. |
Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
|
|
DK2009000T3
(da)
|
2003-01-16 |
2011-09-05 |
Acadia Pharm Inc |
Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
|
|
CN1741803A
(zh)
|
2003-01-23 |
2006-03-01 |
阿卡蒂亚药品公司 |
N－脱甲基氯氮平在治疗人神经精神疾病中的用途
|
|
CA2547639A1
(en)
|
2003-12-02 |
2005-06-16 |
B&B Beheer Nv |
Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
|
|
EP1576985A1
(en)
|
2004-03-18 |
2005-09-21 |
B&B Beheer NV |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
SG133606A1
(en)
|
2003-12-22 |
2007-07-30 |
Acadia Pharm Inc |
Amino substituted diaryl [a,d] cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
|
|
US7820695B2
(en)
|
2004-05-21 |
2010-10-26 |
Acadia Pharmaceuticals, Inc. |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
|
CA2580129A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Acadia Pharmaceuticals Inc. |
Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
|
|
US7790899B2
(en)
|
2004-09-27 |
2010-09-07 |
Acadia Pharmaceuticals, Inc. |
Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
|
|
WO2006096439A2
(en)
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
|
US7803951B2
(en)
|
2005-03-30 |
2010-09-28 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
US20080051429A1
(en)
|
2006-04-19 |
2008-02-28 |
Van Kammen Daniel |
Use of 4-amino-piperidines for treating sleep disorders
|
|
WO2007124136A1
(en)
*
|
2006-04-19 |
2007-11-01 |
Acadia Pharmaceuticals, Inc. |
Use of 4-amino-piperidines for treating sleep disorders
|
|
WO2007133802A2
(en)
|
2006-05-15 |
2007-11-22 |
Acadia Pharmaceuticals Inc. |
Pharmaceutical formulations of pimavanserin
|
|
CA2681506C
(en)
|
2007-03-19 |
2016-05-24 |
Perry Peters |
Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
|
|
WO2008141057A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
|
|
WO2008144665A1
(en)
|
2007-05-18 |
2008-11-27 |
Acadia Pharmaceuticals Inc. |
Use of pimavanserin in the treatment of parkinson and symptoms thereof
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
CA2700332A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
JP2010540454A
(ja)
|
2007-09-21 |
2010-12-24 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ピマバンセリンと他の薬剤との併用投与
|
|
WO2010111353A1
(en)
|
2009-03-25 |
2010-09-30 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
US8927553B2
(en)
|
2009-08-10 |
2015-01-06 |
Daljit Singh Dhanoa |
Deuterium-enriched alkyl sulfonamides and uses thereof
|
|
US9180191B2
(en)
|
2009-10-16 |
2015-11-10 |
University Of South Florida |
Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors
|
|
US7816383B1
(en)
|
2009-12-04 |
2010-10-19 |
Intermune, Inc. |
Methods of administering pirfenidone therapy
|
|
WO2011085216A2
(en)
|
2010-01-08 |
2011-07-14 |
Ironwood Pharmaceuticals, Inc. |
Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
|
|
WO2012002583A1
(en)
|
2010-07-02 |
2012-01-05 |
Vanderbilt University |
Method for treating schizophrenia and related diseases with a combination therapy
|
|
WO2012015712A1
(en)
|
2010-07-30 |
2012-02-02 |
Schering Corporation |
Inhibition of cyp3a drug metabolism
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
EP2556827A1
(en)
|
2011-08-11 |
2013-02-13 |
Acadia Pharmaceuticals Inc. |
Treatment of neurodegenerative diseases
|
|
WO2014085362A1
(en)
|
2012-11-27 |
2014-06-05 |
Acadia Pharmaceuticals Inc. |
Methods for the treatment of parkinson's disease psychosis using pimavanserin
|
|
CN105418460B
(zh)
|
2014-08-11 |
2017-04-12 |
苏州鹏旭医药科技有限公司 |
匹莫范色林及其类似化合物中间体，其制备方法和制备匹莫范色林及其类似化合物的方法
|
|
WO2016141003A1
(en)
*
|
2015-03-02 |
2016-09-09 |
Teva Pharmaceutical Industries Ltd. |
Processes and intermediates for the preparation of pimavanserin
|
|
CN104961672B
(zh)
*
|
2015-05-20 |
2017-10-20 |
沈阳药科大学 |
一种n‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法
|
|
CN104844502B
(zh)
*
|
2015-06-05 |
2018-07-31 |
齐鲁师范学院 |
一种匹莫范色林的制备方法
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
ES2890492T3
(es)
|
2015-07-20 |
2022-01-20 |
Acadia Pharm Inc |
Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
|
|
CN105111135A
(zh)
*
|
2015-09-09 |
2015-12-02 |
安徽省逸欣铭医药科技有限公司 |
取代的尿素衍生物制备方法
|
|
CN106543072A
(zh)
|
2015-09-21 |
2017-03-29 |
天津市汉康医药生物技术有限公司 |
匹莫范色林化合物
|
|
CN105153016B
(zh)
|
2015-10-12 |
2017-10-03 |
北京诺康达医药科技有限公司 |
一种匹莫范色林的制备方法
|
|
CN105481757A
(zh)
|
2015-12-25 |
2016-04-13 |
北京康立生医药技术开发有限公司 |
一种哌马色林的制备方法
|
|
WO2017165635A1
(en)
|
2016-03-25 |
2017-09-28 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome p450 modulators
|
|
US10953000B2
(en)
|
2016-03-25 |
2021-03-23 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome P450 modulators
|
|
US20190117636A1
(en)
|
2016-03-29 |
2019-04-25 |
Acadia Pharmaceuticals Inc. |
5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
|
|
EP3436010B1
(en)
|
2016-03-29 |
2021-03-10 |
Acadia Pharmaceuticals Inc. |
5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
|
|
CN105820110B
(zh)
|
2016-05-09 |
2018-07-24 |
杭州科巢生物科技有限公司 |
匹莫范色林合成方法
|
|
EP3558311A1
(en)
|
2016-12-20 |
2019-10-30 |
Acadia Pharmaceuticals Inc. |
Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
|
|
EP3615028A1
(en)
|
2017-04-28 |
2020-03-04 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for treating impulse control disorder
|
|
EP3675827A1
(en)
|
2017-08-30 |
2020-07-08 |
Acadia Pharmaceuticals Inc. |
Formulations of pimavanserin
|
|
WO2019177973A1
(en)
|
2018-03-13 |
2019-09-19 |
Acadia Pharmaceuticals Inc. |
Methods for assessing suicidality
|
|
US20220016101A1
(en)
|
2018-10-30 |
2022-01-20 |
Acadia Pharmaceuticals Inc. |
Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
|
|
WO2021016369A1
(en)
|
2019-07-22 |
2021-01-28 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
|
|
US20220323429A1
(en)
|
2019-08-15 |
2022-10-13 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for treating neurodegenerative diseases
|
|
US20210161880A1
(en)
|
2019-12-02 |
2021-06-03 |
Acadia Pharmaceuticals Inc. |
Methods for treating dementia related psychosis
|
|
WO2022094230A1
(en)
|
2020-11-02 |
2022-05-05 |
Acadia Pharmaceuticals Inc. |
Compounds for treating psychosis or depression
|